Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

Transaction to support potential commercialization of neffy™, ARS’s needle-free epinephrine nasal spray Well-funded with at least three years of operating runway expectedCompanies to host conference call today, July 21, 2022, at 5:00 p.m. ET SEATTLE and SAN DIEGO – July 21, 2022 – Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) and ARS...

ARS Pharmaceuticals Appoints Eric Karas as Chief Commercial Officer and Kathleen Scott as Chief Financial Officer

Appointments Further Strengthen Leadership Team to Support Launch Preparations for neffy™ (epinephrine nasal spray) SAN DIEGO - April 05, 2022 - ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive...

ARS Pharmaceuticals Expands Executive Leadership Team with Addition of Pharmaceutical Commercialization Veterans

 SAN DIEGO - February 09, 2022 – ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with the appointments of Harris Kaplan as executive...

ARS Pharmaceuticals, Inc. to Share New Data at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Data will highlight patient outcomes of pharmacokinetics, pharmacodynamics, and safety of neffy™ (ARS-1), with simple intranasal epinephrine administration and other epinephrine intramuscular injection devicesSAN DIEGO - February 2, 2022 – ARS Pharmaceuticals, Inc., will share new data on neffy highlighting our innovative intranasal treatment of type 1 severe allergic reactions...